Herriot Tabuteau

AXSM CEO Herriot Tabuteau sold 49.7K shares ($12.0M) at $241.01; retains 7.2K shares plus 99,330 stock options

CEO Herriot Tabuteau executed a pre-arranged 10b5-1 trading plan sale on 2026-06-09, disposing of 49,670 shares valued at $11,970,966.70 while retaining 7,229 non-derivative shares and derivative holdings of 99,330 shares via stock options. The sale occurred at $241.01, near the 52-week high of $242.41 and against a backdrop of 13.0% gains over 30 days and 54.0% gains over 90 days. Axsome remains unprofitable (full-year net income: $-64,542,000.00) despite strong revenue growth of 65.6% year-over-year. His prior five trades at this ticker show mixed post-sale performance (30-day range -11.6% to +20.6%, 90-day range -1.6% to +11.3%), with no consistent directional pattern, making this scheduled sale a neutral data point on conviction rather than a discretionary signal.

CEO TABUTEAU HERRIOT sold 32,410 shares of AXSM for $6.0M; divested 81.8% of holdings.

Chief Executive Officer TABUTEAU HERRIOT executed a substantial open-market sale of 32,410 shares at $185.60 on 2026-02-02, reducing his position from 39,639 shares to 7,229 shares—an 81.8% reduction. The sale was executed near the 52-week high of $189.10, within 1.7% of peak, while the stock has gained 4.0% over the prior 30 days and 37.8% over 90 days. The timing aligns with strong recent price momentum, though context matters: across his cross-ticker track record, his 15 prior sells averaged 90-day returns of +36.9%, indicating his prior sells have not been well-timed (higher subsequent returns mean missed gains). At AXSM specifically, his five prior trades in this same ticker since December 2025 were all sales, with measurable 30-day outcomes of +20.6% and +21.6%, again suggesting post-sale rallies. The company remains unprofitable ($-47.2M net income in the latest full year) despite strong revenue growth of +42.5%, creating a backdrop where leadership liquidity decisions warrant attention. This is the CEO's most significant single sale in the recent sequence.

CEO Tabuteau Herriot sold 139,414 shares for $23,881,617.52 in 3 sales (Jan 5–7), leaving 7,229 shares post-transaction (-95.1% of holdings).

CEO Tabuteau Herriot executed 3 separate sales totaling 139,414 shares for $23,881,617.52 across three consecutive trading days (Jan 5–7, 2026), at prices ranging from $170.38 to $172.33 and a blended average of $171.30. This represents a near-complete exit, reducing holdings from 146,643 shares to 7,229 shares, a -95.1% reduction in position size. The sales occurred while AXSM traded near its 52-week high ($182.64), approximately $0.61 below current price of $170.69, and in the context of 39.3% 90-day price appreciation. His prior trade history at AXSM shows 5 consecutive sales in November and early December 2025—all of which posted positive 30-day returns (10.6% to 26.3%)—establishing a pattern of frequent liquidations near elevated price points. The company remains unprofitable (net income $-47,229,000.00 on revenue of $170,992,000.00), and the scale and proximity of this exit to recent prior sales warrants scrutiny of whether this reflects conviction-level capital redeployment or systematic de-risking.

CEO Herriot sells 79,973 shares at $145.66 avg for $11.6M, reducing stake by -91.7%

TABUTEAU HERRIOT, Chief Executive Officer, executed 3 separate sales totaling 79,973 shares (80.0K shares) for $11,648,582.34 ($11.6M) between December 2–4, 2025, at a blended average price of $145.66 per share. This sale reduced his holdings from 87,202 shares (87.2K shares) to 7,229 shares (7.2K shares), a reduction of -91.7% versus pre-transaction holdings. Axsome Therapeutics remains unprofitable, with net income of $-47,229,000.00 ($-47.2M) over its most recent full fiscal year, despite strong revenue growth of +42.5% year-over-year and a market cap of $7,463,087,225.60 ($7.5B). The CEO's substantial liquidation of personal holdings at a price near the 52-week high (current price $148.04 is -2.3% from the $151.50 peak) occurs amid the company's transition from significant losses toward profitability, and his prior pattern at this ticker shows 5 recent sells (between October 7 and November 5, 2025), each subsequently followed by positive 30-day returns ranging from +10.6% to +17.4%, indicating he has sold into strength without capturing subsequent gains.

CEO TABUTEAU HERRIOT sold 163,939 shares for $21,815,669.06 (-95.8% of holdings) at blended $133.07; stock +30.1% in 90 days

TABUTEAU HERRIOT executed 3 separate sales totaling 163,939 shares for $21,815,669.06 across November 3–5, 2025, reducing his holdings by 95.8% from 171,168 shares to 7,229 shares. The timing is notable: these sales occurred when the stock was near its 52-week high ($137.75), with the current price at $135.69 only 1.5% below that peak and the stock up 30.1% over 90 days. His cross-ticker track record shows 6 prior open-market sells with an average 30-day return of +8.8%, while his 5 prior AXSM trades have all been sells, the most recent (2025-10-08, 10-07) still awaiting measurable outcomes. The company's fundamentals reveal a growing but unprofitable operation: $171.0M in latest-quarter revenue (+42.5% annual growth) against a net loss of $47.2M. The near-complete liquidation of a CEO's position at a company-near-52-week-highs amid strong price appreciation and unprofitability warrants investor scrutiny of whether valuation and execution confidence remain aligned.

AXSM CEO Tabuteau Herriot sold 45,384 shares (86.3% of holdings) for $5,418,059.86 over 3 days; stock now unprofitable.

Tabuteau Herriot, the Chief Executive Officer of Axsome Therapeutics, executed three separate sales totaling 45,384 shares for $5,418,059.86 between October 6–8, 2025, at prices ranging from $118.77–$120.17. This sale reduced his holdings by 86.3%, leaving him with only 7,229 shares post-transaction. The company is unprofitable with net income of $-47,973,000.00 over its most recent full fiscal year, despite achieving strong annual revenue growth of +42.5%. The timing of this substantial equity liquidation by the CEO—while the company is loss-making and the stock has declined 8.2% over the past 30 days—merits investor scrutiny regarding the executive's conviction in near-term prospects. The absence of prior same-ticker trade outcomes (all three recent AXSM sales from September occurred after this October filing) limits assessment of whether this CEO has demonstrated reliable sell-timing at this ticker specifically.

CEO Tabuteau Herriot sold 62,880 shares (62.9K) for $7.4M across 3 sales (Sep 12-16), reducing stake by 89.7% to 7,229 shares.

Tabuteau Herriot, Axsome Therapeutics' CEO, executed 3 separate sales totaling 62,880 shares for $7,361,891.31 at a blended average price of $117.08, leaving a post-transaction holding of only 7,229 shares versus 70,109 pre-transaction. This represents a 89.7% reduction in his equity stake over a 4-day window (Sep 12-16). The company is operating at substantial scale (Revenue $150,042,000.00 in the latest quarter with +42.5% annual revenue growth) but remains unprofitable (net income $-47,973,000.00 over its most recent full fiscal year). The magnitude of the stake reduction is material: the CEO retained less than 10% of his prior holdings, and given Axsome's pre-revenue profitability status, this disposition warrants examination into the executive's capital reallocation priorities relative to the company's investment thesis.